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Objective 2 
To determine the suitability of alfaxalone total intravenous anaesthesia in horses and concurrently 3 
evaluate infusion rates, cardiovascular effects, pharmacokinetics and the quality of the anaesthetic 4 
recovery period.  5 
 6 
Study Design   7 
Prospective, experimental study. 8 
 9 
Animals 10 
Eight Standardbred horses. 11 
 12 
Methods 13 
Horses were premedicated with intravenous (IV) acepromazine (0.03 mg kg-1) and xylazine (1 mg 14 
kg-1) and anaesthesia was induced with guaifenesin  (35 mg kg-1) and alfaxalone (1 mg kg-1).  15 
Anaesthesia was maintained for 180 minutes using an IV infusion of alfaxalone at a rate determined 16 
by a horse’s response to a supramaximal electrical noxious stimulus.  Venous blood samples were 17 
regularly collected to determine alfaxalone plasma concentrations and for pharmacokinetic analysis.  18 
Cardiopulmonary variables were monitored and the quality of the anaesthetic recovery period 19 
scored. 20 
 21 
Results 22 
The median (range) alfaxalone infusion rate was 3.1 (2.4 – 4.3) mg kg-1 hour-1. The mean (± SD) 23 
plasma elimination half-life, plasma clearance and volume of distribution for alfaxalone were 41 24 
minutes, 25 (± 6.3) mL minute-1 kg-1 and 1.6 (± 0.5) L kg-1, respectively.   During anaesthesia, mean 25 
arterial blood pressure was maintained above 70 mm Hg in all horses.  Cardiac index reached a 26 
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minimum value (68% of baseline values) immediately after induction of anaesthesia and was 27 
maintained between 74 and 90% of baseline values for the remainder of the anaesthetic.  Following 28 
the cessation of the alfaxalone infusion, 6 of 8 horses exhibited muscle tremors and paddling.  All 29 
horses stood without incident on the first or second attempt with a median recovery score of 4.5 30 
(good to excellent).  31 
 32 
Conclusions  33 
Anaesthesia in horses can be maintained with an infusion of alfaxalone at approximately 3 mg kg-1 34 
hour-1. The alfaxalone infusion rates used resulted in minimal haemodynamic changes and good 35 
recovery quality. Mean alfaxalone plasma concentration was stable over the infusion period and 36 
clearance rates were similar to a previously published single dose alfaxalone studies in horses. 37 
 38 
Introduction  39 
Alfaxalone formulated in 2-hydroxypropyl-beta-cyclodextrin (HPCD), is a neurosteroid molecule 40 
that interacts with the gamma aminobutyric acid (GABA)A receptor to produce anaesthesia and 41 
muscle relaxation. In horses, alfaxalone has been shown to have a number of pharmacodynamic and 42 
pharmacokinetic properties that suggest it is suitable to for maintenance of total intravenous 43 
anaesthesia (TIVA). For example, following administration of a single dose to premedicated adult 44 
horses and foals, alfaxalone has been shown to have a rapid onset of action, result in a short 45 
duration of recumbency and satisfactory recoveries from anaesthesia. Additionally in horses and 46 
foals alfaxalone is rapidly cleared from the plasma with plasma clearances reported to be 37 and 20 47 
mL minute-1 kg-1, respectively (Goodwin et al. 2011; Goodwin et al. 2012).   48 
 49 
Alfaxalone infusions have been used alone or with various combinations of other infused drugs 50 
such as medetomidine, guaifenesin and butorphanol to maintain anaesthesia in horses and ponies 51 
undergoing castration for up to 60 minutes (Goodwin et al. 2013; Ohmura et al. 2016; Aoki et al. 52 
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with other drugs, was suitable for short term anaesthetic maintenance in horses and ponies; however 54 
there is no information regarding the use of alfaxalone as the sole agent to maintain anaesthesia for 55 
periods longer than 60 minutes.  56 
 57 
The primary objective of this study was to determine if alfaxalone could be used as the sole agent to 58 
maintain anaesthesia in horses for 180 minutes and to concurrently report the alfaxalone infusion 59 
rates, the cardiovascular effects during the alfaxalone infusion, the quality of the anaesthetic 60 
recovery period and the pharmacokinetics.  61 
 62 
Materials and Methods 63 
Animals  64 
This study was performed with approval of The University of Queensland Animal Ethics 65 
Committee (SVS/435/06/UQ).  Eight standardbred horses (4 mares, 4 geldings) with mean (± SD) 66 
age and weights of 9 (± 2) years and 441 (± 40) kg, respectively, from The University of 67 
Queensland Research Herd were included in the study.  Horses were considered healthy on the 68 
morning of the study based on physical examination and haematological and blood biochemical 69 
analysis.  70 
 71 
Instrumentation 72 
A 3.25 inch 14 gauge catheter (BD Angiocath; Becton Dickinson Inc., UT, USA) was placed in the 73 
right jugular vein for drug administration and a second catheter placed in the left jugular vein for 74 
venous blood collection.  A 20 gauge 2 inch catheter (Optiva, Smiths Medical Australasia Pty Ltd, 75 
NSW, Australia) was placed in the left carotid artery (previously relocated subcutaneously) for 76 
arterial blood pressure monitoring and collection of blood for gas analysis.  Two 8.5 French gauge 77 
introducers (Percutaneous Sheath Introducer Set, Arrow International, OH, USA) were placed in the 78 
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right jugular vein approximately 15 cm apart.  A 7 French gauge, 110 cm, thermodilution catheter 79 
(Hands-Off Heparin Coated Thermodilution Catheter, Arrow International, OH, USA) was placed 80 
via the distal introducer into the pulmonary artery (PA) and an 8 French gauge 70 cm catheter 81 
(Devon open-end catheter, Devon Innovations, India) was placed via the proximal introducer into 82 
the right atrium (RA) to administer the injectate for the cardiac output (CO) determination and to 83 
measure central venous pressure (CVP).  Catheters were connected via saline solution filled lines to 84 
pressure transducers (Single transducer BD BTXPlus, Becton Dickinson Inc, Singapore) and a 85 
Marquette Eagle 4000 Patient Monitor (Marquette Electronics Inc, WI, USA). Correct positioning 86 
was confirmed by characteristic blood pressure waves.  The left carotid catheter was connected via 87 
a saline solution filled line to a transducer (MLT0670 Disposable BP Transducer, ADInstruments, 88 
NSW, Australia) and a Powerlab data acquisition system (ADInstruments Pty Ltd, NSW, 89 
Australia).  Transducers were zeroed at the level of the shoulder for standing horses and the sternum 90 
for anaesthetised horses. 91 
 92 
Anaesthetic protocol 93 
After instrumentation, horses were premedicated with acepromazine 0.03 mg kg-1 IV (A.C.P. 10, 94 
Delvet Pty. Ltd., NSW, Australia) followed 20 minutes later by xylazine 1 mg kg-1 IV (Xylazil 100, 95 
Troy Laboratories Pty. Ltd., NSW, Australia).  Five minutes later horses received guaifenesin  (35 96 
mg kg-1 IV) (Giafen, Parnell Pty. Ltd., NSW, Australia) and alfaxalone (1 mg kg-1 IV) (Alfaxan, 97 
Jurox Pty. Ltd, NSW, Australia).  The time from end of the alfaxalone administration to when 98 
horses became laterally recumbent was recorded.  The quality of induction was assessed by a 99 
veterinarian experienced in equine anaesthesia as previously described (1-5 with 5 representing 100 
optimal induction)  (Goodwin et al. 2011).   101 
 102 
Once recumbent, horses were positioned in left lateral recumbency on a high density foam mattress 103 
and the trachea intubated with a 28 mm internal diameter cuffed endotracheal tube.  The ease of 104 
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animal circle system (Easy Veterinary Equipment, NSW, Australia) and oxygen supplied at 6 L 106 
minute-1. Mechanical ventilation (MV) commenced if  horses became apnoeic (no spontaneous 107 
ventilation for 60 seconds) or if PaCO2 was above 70 mmHg (9.3 kPa).  Mechanical ventilation was 108 
performed manually with a 30 L rebreathing bag with an inspiratory time of  2 seconds and a peak 109 
inspiratory pressure of 20 cmH2O.  Frequent attempts were made to restore spontaneous ventilation; 110 
however these attempts were abandoned if PaCO2 remained above 70 mmHg (9.3 kPa).   The 111 
urinary bladder was catheterised to permit continuous drainage during anaesthesia.   112 
 113 
Anaesthesia was maintained with an infusion of alfaxalone (5 mg mL-1 in 0.9% Sodium Chloride; 114 
Baxter Healthcare Pty. Ltd., NSW, Australia) for 180 minutes.  Based on data from preliminary 115 
trials the alfaxalone infusion was started at 5 mg kg-1 hour-1 delivered by a calibrated infusion pump 116 
(IMED Gemini PC-1 infusion pump, Alaris Medical Systems Inc, CA, USA) (Goodwin 2013).  The 117 
alfaxalone infusion rate was adjusted based on the horses’ response to a supramaximal noxious 118 
stimulus that was applied approximately every 20 minutes after induction of anaesthesia.  Two 119 
surface electrodes (inter-electrode distance of 1 cm) were applied to the oral mucous membranes to 120 
deliver an electrical stimulation (50V at a frequency of 5 Hz, 10 milliseconds) for 60 seconds.    A 121 
response was considered positive if purposeful, gross movement of the head or limbs occurred.  If 122 
no positive response occurred within 60 seconds of applying the electrical stimulus the alfaxalone 123 
infusion was decreased by 30% of the preceding infusion rate.  Conversely, if a positive response 124 
occurred the alfaxalone infusion was increased by 30% of the preceding infusion rate.  For each 125 
horse, the infusion rates and any bolus doses of alfaxalone administered were recorded and used to 126 
calculate the total alfaxalone administered during the infusion period. The time intervals from the 127 
end of anaesthesia (cessation of alfaxalone infusion) to tracheal extubation (swallowing), first head 128 
lift, sternal recumbency and standing were recorded.  The quality of recovery from anaesthesia was 129 
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scored as previously described (1-5 with 5 representing optimal recovery) (Goodwin et al. 2011).  130 
Once horses were extubated, oxygen was insufflated via an intranasal tube at 15 L minute-1. 131 
 132 
Cardiopulmonary Measurements 133 
Cardiopulmonary variables were recorded before drug administration (baseline), immediately prior 134 
to induction of anaesthesia (post premedication), within 10 minutes of induction of anaesthesia 135 
(induction) and then every 20 minutes just prior to application of electrical stimulation for the 136 
remainder of the anaesthetic period.  A continuous electrocardiogram (ECG) (base-apex lead), heart 137 
rate (HR), direct arterial blood pressure and respiratory rate (fR) were recorded using the Powerlab 138 
data acquisition system.  Arterial blood samples were collected anaerobically from the carotid artery 139 
and analysed immediately using a Vetstat Analyser (Idexx Laboratories, Westbrook, ME, USA) for 140 
pH, PaO2, PaCO2 and HCO3.  Cardiac output was measured using the thermodilution technique 141 
with 30 mL of 0°C 5% dextrose manually injected over approximately 3 seconds through the RA 142 
catheter at the end of expiration.  The temperature fluctuation was measured using the 143 
thermodilution catheter positioned in the PA and CO calculated by the monitor software.  Cardiac 144 
output and CVP measurements were made three times at each time point and the average recorded.  145 
Cardiac Index (CI), systemic vascular resistance (SVR) and stroke volume (SV) were calculated 146 
using standard formulae (Scharzwald et al. 2009). 147 
 148 
Determination of plasma alfaxalone concentration 149 
Venous blood samples were collected before premedication and at 2, 30, 60, 90, 120, 150, 180, 240, 150 
300, 360, 420 and 480 minutes after the induction dose of alfaxalone had been administered for the 151 
determination of plasma alfaxalone concentrations.   Sample collection, storage, processing and 152 
plasma extraction were as previously described (Goodwin et al. 2011). Plasma alfaxalone 153 
concentrations were determined using a liquid chromatography/tandem mass spectrometry assay 154 
validated in horses (Goodwin et al. 2011).  155 
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 156 
Pharmacokinetic analysis 157 
For plasma alfaxalone concentration, non-compartmental pharmacokinetic analysis using 158 
WinNonlin® Professional (version 5.3; Pharsight Corp., St. Louis, MO, USA) was used to calculate 159 
secondary pharmacokinetic variables including area under the curve to the last quantifiable time 160 
point (AUC0-Tlast), area under the curve to infinity (AUC0-inf), area under the curve percentage 161 
extrapolated (AUCextrap), volume of distribution based on terminal elimination phase (Vz), volume 162 
of distribution at steady state (Vss), total body clearance (Cl), terminal elimination first order rate 163 
constant (lambda_z) and terminal elimination half-life (t1/2_Lambda_z). Maximum observed plasma 164 
alfaxalone concentration (Cmax) and time at maximum observed plasma alfaxalone concentration 165 
values (Tmax) were taken directly from the individual plasma alfaxalone over time curves while 166 
AUC0-Tlast, AUC0-inf and AUCextrap, Vz, Vss, Cl, lambda_z and t1/2_Lambda_z were calculated/estimated 167 
(Table 1).  168 
 169 
Plasma alfaxalone concentration values < LLOQ (lower limit of quantification) were assumed to be 170 
zero when they occurred before the first value > LLOQ. The harmonic mean was calculated using 171 
the HARMEAN() function in Microsoft Office Excel 2007 (Microsoft Corporation, WA, USA): 172 
Harmonic mean = N/(1/a1 + 1/a2…+1/aN) where N is the number of data points and “a” is an 173 
individual data point. 174 
 175 
Statistical Analysis 176 
Data is presented as median and ranges and pharmacokinetic parameters as mean, standard 177 
deviation and range. For cardiopulmonary variables, line graphs were used to analyse changes over 178 
time, box plots to assess the presence of outliers and Shapiro-Wilk’s test to check for normality. 179 
Normally distributed variables (pH and HCO3-) at baseline and then at designated time points after 180 
premedication and induction of anaesthesia were compared using repeated measures ANOVA with 181 
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distributed) at baseline and then at designated time points after premedication and induction of 183 
anaesthesia were compared using the Friedman’s test. Level of significance for all tests was p < 184 
0.05. All calculations were performed using R version 3.42 (R Foundation for Statistical 185 
Computing, Vienna, Austria). A sample size of eight horses was used as this was the maximum 186 
number of animals able to be accommodated with the available resources. 187 
 188 
Results 189 
Induction of anaesthesia 190 
Following induction of anaesthesia with alfaxalone, the median (range) time taken for horses to 191 
become laterally recumbent was 53 (38-70) seconds.  Induction of anaesthesia was smooth for all 192 
horses and the median score for quality of anaesthetic induction was 5 (excellent) (4 - 5). The ease 193 
of endotracheal intubation was scored as 3 (no swallowing, intubated easily) for all horses. 194 
 195 
Infusion of alfaxalone  196 
The alfaxalone infusion started 1.75  (1.2 - 6.1) minutes after the end of the alfaxalone induction 197 
injection and was infused for 180.5 (178.9 - 182.6) minutes at rate of  3.1 (2.4 – 4.3) mg kg-1 hour-1.   198 
Individual horse alfaxalone infusion rates and response to noxious stimulus are shown in Table 2. 199 
Most horses demonstrated brisk palpebral reflexes, intermittent nystagmus and swallowing 200 
throughout anaesthesia but this was not consistently associated with gross purposeful movement. 201 
Positive reactions mostly consisted of gentle limb and head movement or slow paddling of all four 202 
limbs.   203 
 204 
Alfaxalone plasma levels and pharmacokinetics  205 
The pharmacokinetic estimates for individual horses are shown in Table 3. The mean (± SD) Cl, Vd 206 
and t1/2elim was 25 ± 6.3 mL minute-1 kg-1, 1.57 ± 0.53 L kg-1 and 41 minutes, respectively. After the 207 
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three horses and 300 minutes in one horse. The individual alfaxalone plasma concentrations over 209 
time for individual horses are shown in Figure 1.  210 
 211 
Haemodynamic variables  212 
No ECG abnormalities were observed during the anaesthetic period.  Overall, there was a 213 
significant difference for all cardiovascular variables when the infusion period was compared with 214 
baseline values; however, smaller but still significant differences were noted when baseline values 215 
were compared with values for each variable taken every 20 minutes during the infusion (Table 4).  216 
Although not statistically significant, CI reached a minimum value immediately after induction of 217 
anaesthesia (68% of baseline values) and was maintained between 74 and 90% of baseline values 218 
for the remainder of the anaesthetic. Stroke volume and CVP trended downwards as the infusion 219 
progressed.  Systemic vascular resistance tended to increase during the infusion period and was 220 
significantly increased from baseline at 100 (p = 0.045), 120 (p = 0.045) , 160 (p = 0.045)  and 180 221 
(p = 0.044) minutes.  Arterial blood pressure and heart rate also trended upwards towards the end of 222 
the infusion. Mean arterial pressure (MAP) and DAP were significantly different from baseline at 223 
60 and 80 minutes (p = 0.04) and 40, 60, 140, 160 and 180 minutes (p = 0.038), respectively.  224 
 225 
Respiratory rate and arterial blood gases 226 
Six horses became apnoeic during anesthesia and required MV for the majority of the anaesthetic 227 
period.  As for cardiovascular variables, there was an overall significant difference for respiratory 228 
rate and arterial blood gases when the infusion period was compared with baseline values; however 229 
smaller but still significant differences were noted when baseline values were compared with values 230 
for each variable taken every 20 minutes during the infusion (Table 5). Significant increases in 231 
PaCO2 (p = 0.04) and HCO3- (p < 0.01) and decreases in pH (p < 0.01) values compared with 232 
baseline were observed from 20 – 180 minutes of the infusion.  233 
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 234 
Recovery 235 
The time to extubation after discontinuation of the infusion was 5 (1-14) minutes.  Time to first 236 
head lift, achieving sternal recumbency and standing was 18 (12-64), 65.5 (35-118) and 90.5 (64-237 
129) minutes, respectively.  Approximately 10 to 20 minutes after the cessation of the alfaxalone 238 
infusion, six of eight horses exhibited some form of central nervous system excitation that ranged 239 
from mild muscle tremors and twitching to profound paddling and muscle rigidity.  These episodes 240 
were intermittent over a maximum period of 25 minutes and appeared to be precipitated by noise 241 
and tactile stimuli.  Despite this, all horses stood without incident on the first or second attempt and 242 
the median recovery score was 4.5; good to excellent (range 3 - 5).   243 
 244 
Discussion 245 
The results of this study suggest an infusion of alfaxalone can be used as the sole agent to maintain 246 
TIVA for 180 minutes in horses.  The anaesthetic technique resulted in a smooth anaesthetic 247 
induction and good preservation of cardiovascular function.  Recovery from anaesthesia was 248 
satisfactory; however, some horses exhibited muscle tremors and paddling soon after the alfaxalone 249 
infusion was ceased.  250 
 251 
During the study, horses were electrically stimulated to mimic a surgical stimulus and the 252 
alfaxalone infusion rate adjusted in an attempt to achieve a light depth of anaesthesia. Due to the 253 
experimental design, anaesthesia would have been inadequate for clinical use as all horses moved at 254 
some stage during the alfaxalone infusion in response to stimulation.  Also, some unstimulated 255 
horses moved spontaneously (Table 2) and it was often difficult to judge the depth of anaesthesia 256 
and anticipate a response to stimulation. For example, despite displaying brisk palpebral reflexes, 257 
nystagmus and swallowing, horses would often not move in response to stimulation. Brisk palpebral 258 
movements, nystagmus and skeletal muscle twitching not associated with gross purposeful 259 
movement or depth of anaesthesia was reported in goats receiving infusions of alfaxalone during 260 
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is a concept similar to minimum alveolar concentration (MAC) and is defined as the infusion rate 262 
that will prevent movement in response to surgical stimulation in 50% of patients (Prys-Roberts 263 
1980). This study was not designed to determine the MIR; however, horses were lightly 264 
anaesthetised and it is possible the calculated infusion rates may more closely approximate the MIR 265 
than alfaxalone infusion rates that are appropriate for clinical use in horses.  266 
 267 
Previously, lower alfaxalone infusion rates (1.5 – 2 mg kg-1 hour-1) co-infused with various 268 
combinations of medetomidine, guaifenesin and butorphanol were reported to provide an adequate 269 
depth of anaesthesia for horses anaesthetised for 45 - 60 minutes during castration surgery 270 
(Goodwin et al. 2013; Ohmura et al. 2016; Aoki et al. 2017). In retrospect, the initial alfaxalone 271 
infusion rate of 5 mg kg-1 hour-1 used in this study was too high as most horses did not respond to 272 
the noxious stimulus until they were receiving considerably lower infusion rates (1.25 – 1.75 mg kg-273 
1
 hour-1) approximately 60 minutes after the infusion began. This was likely due to the effects of the 274 
acepromazine, xylazine and guaifenesin acting additively and/or synergistically with alfaxalone to 275 
lower the total amount of alfaxalone required to maintain anaesthesia. It is also possible that these 276 
drugs altered haemodynamics, drug perfusion and the redistribution of alfaxalone and the 277 
concentration of the drug at the target receptor site. Consequently, in future clinical studies it will be 278 
important to  account for the effects of premedication by starting at lower alfaxalone infusion rates 279 
and possibly incorporating a “step-up” process that sequentially increases the infusion rate during 280 
the first 60 minutes of anaesthesia.  281 
 282 
Maintenance of adequate cardiovascular function is essential during anaesthesia of horses. In this 283 
study CI was well maintained during anaesthesia and ranged from  284 
48 to 63 mL minute-1  kg-1 representing a reduction from baseline values of approximately 32 to 285 
10%.  The greatest reduction in CI was noted immediately after induction of anaesthesia (32%) and 286 
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Heart rate was also well maintained and tended to increase during the infusion and may have helped 288 
to maintain CI. It is likely that the premedicants in this study contributed to the drop in CI after 289 
induction of anaesthesia and early into the anaesthetic maintenance period. The administration of 290 
the same dose of xylazine to standing horses has been shown to reduce CI by approximately 50% 291 
with the effects greatest 5 minutes after administration and continuing to significantly reduce CI 292 
from baseline values for 40 minutes (Yamashita et al. 2000).   293 
 294 
A MAP above 70 mmHg is considered necessary to prevent the development of postoperative 295 
myopathies in anaesthetised horses (Duke et al. 2006) and all horses in the current study maintained 296 
MAP above 70 mmHg without the use of sympathomimetic drugs. Systemic vascular resistance 297 
was also well maintained and significantly increased compared with baseline values towards the 298 
end of the infusion; therefore, suggesting that minimal vasodilation occurred. These findings are in 299 
agreement with studies of alfaxalone in other species, such as cats, dogs and sheep, where good 300 
haemodynamic stability has also been reported (Ambros et al. 2008; Muir et al. 2008; Muir et al. 301 
2009; Granados et al. 2012).   302 
 303 
In the current study, six of eight horses became apnoeic and required MV.  Mechanical ventilation 304 
was discontinued at intervals as the authors were interested to observe if adequate ventilation would 305 
occur when horses were lightly anaesthetised.  However, adequate spontaneous ventilation did not 306 
occur and consequently for the majority of the anaesthetic period respiratory depression was 307 
evident. Dose dependent respiratory depression has been described in dogs and cats receiving a 308 
single bolus or an infusion of alfaxalone (Ambros et al. 2008; Muir et al. 2009; Keates & Whittem 309 
2012); however, definitive conclusions regarding the respiratory effects of alfaxalone on horses 310 
cannot be drawn from this study. It is noted that interpretation of the haemodynamic variables in 311 
this study may have been confounded by the indirect sympathomimetic effects of increased PaCO2 312 
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which is generally associated with improved haemodynamics (Wagner et al. 1990). Conversely, the 313 
use of MV can cause detrimental cardiovacular effects and may have negatively influenced 314 
haemodynamic variables in this study (Hodgson et al. 1986).  315 
 316 
While FiO2 was not recorded, PaO2 was generally well maintained, although lower than expected 317 
for horses breathing 100% oxygen via a circle system. This may have been due to hypoventilation, 318 
however, other factors commonly associated with recumbency and general anaesthesia in horses, 319 
such as ventilation-perfusion mismatching and intra-pulmonary shunts, are also likely to have 320 
contributed to the lower PaO2 values observed (Nyman & Hedenstierna 1989; Nyman et al. 1990).   321 
Further work to investigate the pulmonary effects of alfaxalone in horses is required; however, 322 
based on these preliminary findings, the authors recommend oxygen supplementation and provision 323 
for MV if anaesthesia is maintained with an infusion of alfaxalone alone. 324 
 325 
The pharmacokinetic profile of alfaxalone in this study was similar to that reported after a single 326 
induction dose of alfaxalone in adult premedicated horses (Goodwin et al. 2011).  Following 180 327 
minutes of infusion, alfaxalone was rapidly cleared from horse plasma at approximately 25 mL 328 
minute-1 kg-1. This corresponds to approximately 32% of CO and represents only a modest 329 
reduction to plasma clearance after a single bolus dose (37 mL minute-1 kg-1, 46% of CO).  The 330 
average volume of distribution (1.6 L) was the same as previously reported for a single bolus dose. 331 
The plasma elimination half-life of alfaxalone after 180 minutes of infusion was only slightly 332 
increased to that reported after a single dose (41 minutes vs 33 minutes). This fact in concert with 333 
similar alfaxalone clearance rates in the single dose and infusion horse studies shows that alfaxalone 334 
is cleared by first order kinetics even after 180 minutes of infusion.  335 
 336 
Horses recovered from anaesthesia to the standing position smoothly with few attempts and was of 337 
a similar quality to anaesthetic recoveries described after short term alfaxalone anaesthesia (Leece 338 
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et al. 2009; Goodwin et al. 2011; Kloppel & Leece 2011; Goodwin et al. 2013).  In this study, the 339 
time taken for horses to achieve the standing position was longer than that reported after a single 340 
dose in premedicated horses (90.5 minutes vs 47 minutes) (Goodwin et al. 2011).  As the mean 341 
elimination half-life of alfaxalone in this study was similar to that observed in the aforementioned 342 
single dose study, it is likely that the longer recovery times are due to changes in physiology 343 
induced by protracted anaesthesia (e.g. decreased core body temperature, reversible muscle 344 
compartmental syndrome). For example, in cats with anaesthesia maintained with a target 345 
controlled infusion of alfaxalone, the context sensitive half time was short regardless of the duration 346 
of the infusion, however the recovery time was predicted to be influenced by the duration of the 347 
infusion (Pypendop et al. 2018).  348 
  349 
Although recovery from anaesthesia to the standing position was satisfactory, early in the recovery 350 
period most horses demonstrated a form of central nervous system excitation as evidenced by 351 
paddling, muscle twitching, and an exaggerated response to noise and handling.    Similar 352 
observations during the anaesthetic recovery period following alfaxalone infusions have also been 353 
reported in cats (Schwarz et al. 2014). It is interesting that central excitation was not observed in 354 
horses receiving lower alfaxalone infusion rates (1.5 - 2 mg kg-1 hour-1) co-infused with 355 
medetomidine alone, medetomidine and guaifenesin or medetomidine and butorphanol for 45 - 60 356 
minutes (Goodwin et al. 2013; Ohmura et al. 2016; Aoki et al. 2017). However, in later preliminary 357 
trials, we again observed a similar degree of central nervous system excitation during the recovery 358 
period of three horses receiving co-infusions of alfaxalone (1.4 - 3.6 mg kg-1 hour-1)  and 359 
medetomidine (3.5 - 5 mg kg-1 hour-1)  for 110-180 minutes (Goodwin 2013).  We hypothesised that 360 
the central nervous effects  may be linked to synaptic plasticity and neuromodulation at the GABAA 361 
and glycine receptor. Lau et al (2010) reported that in an in vitro hypoglossal nerve model, 362 
alfaxalone reduces glycinergic inhibitory transmission which made the nerve more “accessible” to 363 
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excitatory neurotransmission. Clearly, more research is required to elucidate the temporal effects of 364 
alfaxalone and associated endogenous ligands on the GABAA and glycine receptor.   365 
 366 
Limitations of this study include the small number of horses studied and that the 30% change 367 
(increase or decrease) in alfaxalone infusion rate from the preceding rate may have been too small 368 
to result in appreciable differences in concentrations of the drug at the target receptor.  In hindsight, 369 
the study may have been designed to determine the MIR of alfaxalone in horses with the blood 370 
sampling for plasma alfaxalone analysis timed so that Cp50 could also be determined. This was not 371 
done as the authors were more interested in the clinical application of alfaxalone infusions in horses 372 
and to determine alfaxalone infusion rates to be used in a later MAC reduction study (Goodwin 373 
2013).  374 
 375 
In conclusion, alfaxalone infused at approximately 3 mg kg-1 hr-1 for 180 minutes resulted in a 376 
relatively stable maintenance phase of anaesthesia with minimal haemodynamic changes. 377 
Mechanical ventilation and supplemental oxygen were required to overcome respiratory depression 378 
and reduce the incidence of low blood oxygenation.  Most horses stood calmly on the first attempt 379 
although there was a high incidence of central nervous system excitation in the period immediately 380 
following the cessation of the infusion.  Mean alfaxalone plasma concentration was stable over the 381 
infusion period and clearance rates were similar to a previously published single dose alfaxalone 382 
study in horses.  383 
 384 
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Table 1 Pharmacokinetic definitions and how they were calculated for 8 Standardbred horses premedicated with intravenous (IV) acepromazine (0.03 
mg kg-1) and xylazine (1 mg kg-1 IV) and anaesthesia induced with guaifenesin (35 mg kg-1 IV) and alfaxalone (1 mg kg-1 IV) and maintained with a 
variable rate infusion of alfaxalone for 180 minutes. 
  
Pharmacokinetic variable Calculation methods 
Area under the curve from time of drug administration to the last 
quantifiable time point (AUC0-Tlast) (minute mg L-1) 
Calculated using the linear trapezoidal rule (Gibaldi & Perrier 1982) 
 
Area under the curve from time of drug administration to infinity 
(AUC0-inf) (minute mg L-1) 
AUC0-inf = AUC0-Tlast + lambda_z/Clast 
Where Clast equals the last quantifiable alfaxalone plasma 
concentration. 
 
Percentage of AUC0-inf that is due from Tlast (i.e. time of last 
quantifiable alfaxalone concentration) to infinity (AUCextrap) (%) 
AUCextrap(%) = AUC0-Tlast ÷ AUC0-inf × 100%. 
 
Volume of distribution based on terminal phase lambda_z (Vz) (L kg-
1) Vz =	

	 × 

 
Volume of distribution at steady state (Vss) (L kg-1) 
Vss =	
	 × 

(
 − )²
 
Where AUMC is the area under the first moment curve and τ (Tau) is 
the dosing interval. 
Total body clearance (Cl) (mL minute-1 kg-1) Cl =	 


 
First order rate constant associated with the terminal portion of the 
curve (Lamba_z) (mL minute-1) 
The estimate lambda_z was calculated by linear regression on the 
elimination portion of the curve using a best fit approach where n is 
the number of data points in the regression and R2 is the square of the 
correlation coefficient. For each regression an adjusted R2 was 
computed with: 

	R =	
1 − (1 − R)		( − 1)
 − 2
 
Terminal half-life (t1/2_Lambda_z) (minutes)  t1/2_Lambda_z = ln(2)/λz 
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Table 2 Alfaxalone infusion rates (mg kg-1 hr-1), response to nociceptive testing and average infusion rate for 8 Standardbred horses premedicated with 
intravenous (IV) acepromazine (0.03 mg kg-1) and xylazine (1 mg kg-1 IV) and anaesthesia induced with guaifenesin (35 mg kg-1 IV) and alfaxalone (1 
mg kg-1 IV) and maintained with a variable rate infusion of alfaxalone for 180 minutes. 
 
  
Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6 Horse 7 Horse 8 
Time 
(minu
tes) 
Infusio
n  
rate  
Time 
(minu
tes) 
Infusio
n rate 
Time 
(minu
tes) 
Infusio
n rate  
Time  
(minut
es) 
Infusio
n  
rate  
Time  
(minu
tes) 
Infusio
n  
rate  
Time  
(minu
tes) 
Infusio
n  
rate  
Time  
(minu
tes) 
Infusio
n  
rate  
Time  
(minu
tes) 
Infusi
on  
rate  
1.4 5 1.2 5 2 5 1.5 5 2.4 5 2.4 5 6.1 5 1.4 5 
24∨ 3.5 24∨ 3.5 23∨ 3.5 23∨ 3.5 26∨ 3.5 24∨ 3.5 26∨ 3.5 24∨ 3.5 
44∨ 2.5 43∨ 2.5 44∨ 2.5 43∨ 2.5 45∨ 2.5 44∨ 2.5 45∨ 2.5 43∨ 2.5 
61∨ 1.75 63∨ 1.75 64∨ 1.75 64∨ 1.75 65∨ 1.75 64∨ 1.75 66∨ 1.75 64∨ 1.75 
83∧ 2.5 83∨ 1.25 82∧ 2.5 85∨ 1.25 86∨ 1.25 83∧ 2.5 86∨ 1.25 *86∧ 2.5 
103∨ 1.75 104∧ 1.75 104∧ 3.5 106∧ 1.75 89#∧ 1.75 92∧ 3.5 105∧ 1.75 105∧ 3.5 
123∧ 2.5 115#∧ 2.5 124∨ 2.5 125∨ 1.25 96#∧ 2.5 104∧ 5 112#∧ 2.5 125∧ 3.5 
143∨ 1.75 124∧ 3.5 145∧ 3.5 143∧ 1.75 115#∧ 3.5 125∧ 6.5 127∧ 3.5 146∨ 2.5 
163∧ 2.5 135∨ 5 164∨ 2.5 163∧ 2.5 126∨ 2.5 144 6.5 144∧ 5 160∧ 3.5 
183∨ 2.5 144∨ 3.5 182∧ 2.5 182∨ 2.5 147∨ 1.75 164∨ 5 165∨ 3.5 184∨ 3.5 
163∧ 5 154∧ 2.5 183∧ 5 185#∧ 3.5 
      181∨ 5         184∨ 2.5             
Average 
alfaxalone 
infusion  
mg kg-1 
hr-1 
2.7 3.2 3 2.4 2.8 4.3 3.1 3.5 
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Time (min): time from end of alfaxalone induction injection. Infusion rate: alfaxalone infusion rate mg kg-1 minute-1. ∧ Noxious stimulation with 
positive response. ∨ Noxious stimulation with negative/no response. #∧ No stimulation but horse spontaneously moving. *Horse received 100 mg IV 
alfaxalone as attempting to stand. Average infusion rate for each horse calculated at total alfaxalone dose during infusion (mg)/horse weight 
(kg)/infusion time (minutes).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 3 Pharmacokinetic variables estimated by non-compartmental analysis of alfaxalone concentrations in 8 Standardbred horses premedicated with 
intravenous (IV) acepromazine (0.03 mg kg-1) and xylazine (1 mg kg-1 IV) and anaesthesia induced with guaifenesin (35 mg kg-1 IV) and alfaxalone (1 
mg kg-1 IV) and maintained with a variable rate infusion of alfaxalone for 180 minutes. 
 
Horse ID 
Tmax 
(minute) 
 
Cmax 
 (mg L-1) 
 
AUC0-Tlast 
(minute mg 
L-1) 
 
AUC0-inf 
(minute mg 
L-1) 
 
AUCextrap 
 (%) 
 
Vz 
(L kg-1) 
 
Vss 
(L kg-1) 
Cl  
(mL minute-1 
kg-1) 
 
lambda_z 
(mL 
minute-1) 
 
lambda_z 
Half-Life 
(minute) 
 
1 180 2.29 507.6 516.6 
 
1.7 1.13 0.89 17.6 15.6 44.5 
2 180 2.92 491.9 505.9 
 
2.8 2.32 1.37 21 0.9 76.9 
3 30 2.18 407.9 417.6 
 
2.3 1.29 0.78 24.4 18.9 36.6 
4 60 2.64 437.5 417.6 
 
0.7 0.77 0.81 18.6 24.3 28.6 
5 2 3.01 373 378.1 
 
1.3 1.54 0.93 25.4 16.5 42.1 
6 150 2.01 361.2 377.8 
 
4.4 2.24 1.88 37.1 16.6 41.8 
7 150 2.30 366.6 377.8 
 
4.8 1.66 1.42 27 16.3 42.5 
8 180 1.94 361.8 374.2 
 
3.3 1.62 1.17 29.1 18 38.4 
Mean 
(SD) 
116.5  ± 
73.8 
2.41 ± 
0.40 413.4 ± 59.6 420.7 ± 58.7 2.7 ± 1.4 
1.57 ± 
0.53 
1.16 ± 
0.38 25 ± 6.3 16.9 ± 4.2 41* 
Range (2-180) (1.94-3.01) 
(374.2-
516.6) 
(374.2-
516.6) (0.7-4.8) 
(0.77-
2.32) 
(0.78-
1.88) (17.6-37.1) (0.9-24.3) (28.6-76.9) 
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*calculated as harmonic mean. Results expressed as mean ± SD (range). Time of maximum observed plasma concentration (Tmax), observed 
maximum plasma concentration (Cmax), Area under the curve from time of drug administration to the last quantifiable time point (AUC0-Tlast), Area 
under the curve from time of drug administration to infinity (AUC0-inf), percentage of AUC0-inf that is due from Tlast (i.e. time of last quantifiable 
alfaxalone concentration) to infinity (AUCextrap), volume of distribution based on terminal phase lambda_z (Vz), volume of distribution at steady state 
(Vss), total body clearance (Cl), first order rate constant associated with the terminal portion of the curve (Lamba_z) and Terminal half-life 
(t1/2_Lambda_z). 
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Table 4 Cardiac index (CI), systemic vascular resistance (SVR), stroke volume (SV), central venous pressure (CVP), heart rate (HR), mean 
arterial pressure (MAP), diastolic arterial pressure (DAP) and systolic arterial pressure (SAP) in 8 horses during 180 minutes of alfaxalone 
total intravenous anaesthesia.  
 
   Minutes after induction of anaesthesia Overall summary 
during infusion  
 Base-
line 
Post 
premed 
Induction 20 40 60 80 100 120 140 160 180 Median 
(IQR) 
p-value 
 
CI 
(mL  
minute-1 kg-1) 
(n = 8) 
 
65  
(59-
110) 
 
54  
(44-69) 
 
48  
(38-60) 
 
60  
(49-
74) 
 
61  
(55-
79) 
 
56  
(50-76) 
 
58  
(49-
76) 
 
53  
(44-62) 
 
53  
(38-68) 
 
60  
(46-81) 
 
53  
(43-60) 
 
57  
(47-68) 
 
56 
(39) 
 
< 0.001 
 
SVR 
(dynes secs  
cm-5) 
(n = 7) 
 
243  
(111-
331) 
 
317  
(238-
436) 
 
328  
(255-465) 
 
256  
(197-
313) 
 
250  
(176-
257) 
 
237  
(216-
294) 
 
270  
(248-
351) 
 
374*  
(307-
579) 
 
363*  
(301-
644) 
 
362  
(209-
511) 
 
466*  
(258-
578) 
 
400*  
(304-
564) 
 
311 
(395) 
 
< 0.001 
 
SV (mL) 
(n = 7) 
 
815 
(610-
1358) 
 
662 
(539-
700) 
 
626 
(379-1009) 
 
684 
(580-
992) 
 
696  
(578-
975) 
 
626 
(427-
778) 
 
539 
(447-
783) 
 
514  
(480-
671) 
 
549 
(352-
644) 
 
570 
(434-
900) 
 
498 
(411-
665) 
 
578 
(346-
655) 
 
611 
(610) 
 
< 0.001 
 
CVP 
(mm Hg) 
(n = 8) 
 
 
8 
(6-16) 
 
7 
(2-13) 
 
13 
(7-16) 
 
8 
(-3-16) 
 
5 
(1-15) 
 
2 
(1-15) 
 
2 
(-1-13) 
 
2 
(0-15) 
 
4 
(-2-16) 
 
3 
(-3-18) 
 
4 
(-5-16) 
 
3 
(-2-16) 
 
5 
(18) 
 
< 0.001 
HR 
(beats 
minute-1) 
(n = 7) 
36 
(32-
44) 
33 
(28-36) 
35 
(32-42) 
38 
(32-
40) 
38 
(30-
47) 
40 
(35-52) 
41 
(40-
59) 
40 
(37-52) 
40 
(36-72) 
40 
(36-76) 
45 
(38-61) 
42 
(40-57) 
40 
(29) 
< 0.001 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Results at each time point are expressed as median (range). * statistically different compared with baseline values (p < 0.05). Summary of 
overall results as median and interquartile range (IQR) and overall p-value reported for anaesthetic period compared with baseline. 
Baseline values were collected before administration of any drugs, premedication values after xylazine administration and induction values 
immediately after induction of anaesthesia.    Data missing for 1 horse on several variables due to data acquisition failure. 
 
MAP 
(mm Hg) 
(n = 7) 
 
101  
(80-
115) 
 
96  
(82-126) 
 
100  
(83-120) 
 
91  
(73-
110) 
 
82  
(75-
91) 
 
81*  
(78-87) 
 
98  
(76-
125) 
 
112  
(89-
141) 
 
128  
(99-
141) 
 
128  
(96-
140) 
 
130  
(97-147) 
 
134*  
(120-
153) 
 
101 
(65) 
 
< 0.001 
 
DAP 
(mm Hg) 
(n = 7) 
 
89  
(74-
104) 
 
92  
(81-111) 
 
95  
(80-125) 
 
88  
(68-
100) 
 
75*  
(66-
84) 
 
77* 
(71-80) 
 
90  
(75-
115) 
 
101  
(83-
120) 
 
114 
(93-
130) 
 
120*  
(92-
132) 
 
124*  
(92-134) 
 
124*  
(110-
148) 
 
95  
(64) 
 
< 0.001 
 
SAP 
(mm Hg) 
(n = 7) 
 
122  
(87-
133) 
 
109  
(82-129) 
 
105  
(83-134) 
 
100  
(77-
135) 
 
92  
(81-
112) 
 
94  
(83-
106) 
 
108  
(92-
157) 
 
127  
(100-
165) 
 
141  
(111-
168) 
 
150  
(102-
168) 
 
135  
(100-
165) 
 
154  
(130-
176) 
 
115 
(86) 
 
< 0.001 
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Table 5 Respiratory rate (fR), arterial pH (pH), arterial pressure of oxygen (PaO2), arterial pressure of carbon dioxide (PaCO2), and bicarbonate (HCO3-
) in 8 horses during 180 minutes of alfaxalone total intravenous anaesthesia.  
 
   Minutes after induction of anaesthesia Overall summary 
during infusion 
 Base-
line 
Post 
premed 
Induct-
ion 
 
20 
 
40 
 
60 
 
80 
 
100 
 
120 
 
140 
 
160 
 
180 
Median 
(IQR) 
p value 
fR 
(breath 
minute-1) 
 
12 
(8-16) 
 
14 
(10-25) 
 
3 
(1-15) 
 
3 
(1-4) 
 
4 
(2-6) 
 
4 
(2-6) 
 
4 
(2-13) 
 
4 
(2-5) 
 
4 
(2-9) 
 
4 
(2-16) 
 
4 
(2-5) 
 
4 
(2-6) 
 
4  
(15) 
 
< 0.001 
 
pH 
 
7.45 
(7.40-
7.47) 
 
7.44 
(7.39-
7.50) 
 
7.41 
(7.39-
7.48) 
 
7.29* 
(7.22-
7.34) 
 
7.33*  
(7.27-
7.39) 
 
7.34*  
(7.27-
7.40) 
 
7.35*  
(7.25-
7.42) 
 
7.35*  
(7.30-
7.39) 
 
7.35*  
(7.30-
7.42) 
 
7.31* 
(7.19-
7.38) 
 
7.35*  
(7.23-
7.44) 
 
7.33*  
(7.22-
7.36) 
 
7.36  
(0.007) 
 
< 0.001 
 
PaO2  
(mm Hg) 
 
100  
(95-113) 
 
91  
(75-100) 
 
106  
(65-148) 
 
133  
(91-276) 
 
242  
(108-
390) 
 
273  
(110-
355) 
 
223  
(92-389) 
 
309  
(127-
405) 
 
253  
(120-
412) 
 
158  
(112-
385) 
 
190  
(93-398) 
 
213  
(111-
353) 
 
152 
(306) 
 
< 0.001 
(kPa) 13.3 
(12.6-
15) 
12.1 
(10-
13.3) 
14.1 
(8.6-
19.7) 
17.7 
(12.1-
36.8) 
32.2 
(14.4-
52) 
36.4 
(14.6-
47.3 
31 
(12.2-
51.8) 
41.2 
(16.9-
54) 
33.7 
(16-
54.9) 
21 
(14.9-
51.3) 
25.3 
(12.4-53) 
28.4 
(14.8-
47) 
20.2 
(40.8) 
 
 
PaCO2 
(mm Hg) 
 
46  
(44-48) 
 
47  
(42-55) 
 
52  
(41-56) 
 
70*  
(65-86) 
 
62* 
(59-77) 
 
66* 
(55-82) 
 
67* 
(52-75) 
 
65* 
(55-70) 
 
67* 
(48-77) 
 
70* 
(62-101) 
 
66* 
(51-93) 
 
71*  
(65-83) 
 
64 
(42) 
 
< 0.001 
 
(kPa) 
 
6.1  
(5.8-6.4) 
 
6.2 
(5.6-7.3) 
 
6.9 
(5.4-7.4) 
 
9.3* 
(8.6-
11.4) 
 
8.2* 
(7.8-
10.2) 
 
8.8* 
(7.3-
10.9) 
 
8.9* 
(6.9-10) 
 
8.6* 
(7.3-9.3) 
 
8.9* 
(6.4-
10.2) 
 
9.3* 
(8.2-
13.4) 
 
8.8* 
(6.8-
12.5) 
 
9.4* 
(8.6-11) 
8.5 
(5.6) 
 
 
HCO3- 
(mmolL-
1) 
 
28.8  
(26.6-
30.4) 
 
30.1  
(27-
31.5) 
 
30  
(25.9-
31) 
 
32*  
(27.3-
32.9) 
 
32*  
(27.8-
32.7) 
 
33*  
(27.9-
35) 
 
33*  
(30.1-
34.9) 
 
32.7* 
(29.7-
36) 
 
32.9*  
(27.6-
35.1) 
 
33.8*  
(31.3-
35.8) 
 
32.6*  
(30.5-
35.9) 
 
34.2*  
(30.5-
35.3) 
 
31.8 
(2.4) 
 
< 0.001 
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Results at each time point are expressed as median (range). * statistically different compared with baseline values (p < 0.05). Summary of overall 
results as median and interquartile range (IQR) and overall p-value reported for anaesthetic period compared with baseline. Baseline values were 
collected before administration of any drugs, premedication values after xylazine administration and induction values immediately after induction of 
anaesthesia
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ACCEPTED MANUSCRIPTFigure 1 Alfaxalone plasma levels (mg L-1) over time (minutes) in 8 horses premedicated with 
intravenous (IV) acepromazine (0.03 mg kg-1) and xylazine (1 mg kg-1 IV) and anaesthesia induced 
with guaifenesin (35 mg kg-1 IV) and alfaxalone (1 mg kg-1 IV) and maintained with a variable rate 
infusion of alfaxalone for 180 minutes.
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